Compare · CRMD vs OUST
CRMD vs OUST
Side-by-side comparison of CorMedix Inc. (CRMD) and Ouster Inc. (OUST): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while OUST operates in Industrials - the two are in different parts of the market.
- OUST is the larger of the two at $518.2M, about 3.3x CRMD ($155.0M).
- Over the past year, CRMD is down 18.1% and OUST is up 264.6% - OUST leads by 282.7 points.
- OUST has been more active in the news (20 items in the past 4 weeks vs 2 for CRMD).
- OUST has more recent analyst coverage (16 ratings vs 7 for CRMD).
- Company
- CorMedix Inc.
- Ouster Inc.
- Price
- $7.42+1.23%
- $28.22+6.89%
- Market cap
- $155.0M
- $518.2M
- 1M return
- +12.00%
- +39.50%
- 1Y return
- -18.06%
- +264.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 2
- 20
- Recent ratings
- 7
- 16
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Latest CRMD
- SEC Form PRE 14A filed by CorMedix Inc.
- CorMedix to Participate in Needham Virtual Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
- CorMedix to Participate in Upcoming Investor Conferences
- Chief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)
Latest OUST
- Chief Technology Officer Frichtl Mark exercised 400 shares at a strike of $2.13 and sold $12,000 worth of shares (400 units at $30.00) as part of a pre-agreed trading plan (SEC Form 4)
- Ouster BlueCity Selected for Major Traffic Signal Management and Road Safety Deployments Across 30+ Intersections in and around Atlanta, Georgia
- SEC Form 4 filed by Skaggs Stephen A
- SEC Form 4 filed by Frichtl Mark
- SEC Form 144 filed by Ouster Inc.
- SEC Form 4 filed by Frichtl Mark
- SEC Form 4 filed by Chung Megan
- SEC Form PRE 14A filed by Ouster Inc.
- SEC Form 4 filed by Frichtl Mark
- SEC Form 144 filed by Ouster Inc.